## RGNX: REGENXBIO Inc. - XLV: Healthcare

### Executive Summary

STRENGTH thesis confirmed: MRS_20 at 6.5% in lower entry zone (4.0-10.0%), top quartile (89th pct) cross-sectional ranking. Short-term MRS_5 (0.9%) confirms momentum alignment. Outperforming sector by 8.0%. Caution: momentum weakening (-5.5% MRS).

- **Horizon:** 5-20 days (swing)
- **Risk Profile:** Moderate - momentum continuation
- **Stop Type:** Fixed 2xATR ($11.38)
- **If Wrong:** Exit if MRS_20 drops below entry zone or breaks stop
- **Invalidation:** MRS_20 exits entry zone or MRS_5 turns negative

### News

- **Articles:** 1
- **Sentiment:** Bearish (Bullish: 0, Bearish: 0)

**1. JPMorgan Chase & Co. Sells 512,318 Shares of REGENXBIO Inc. $RGNX**
- Source: MarketBeat | 20251204T050346 | Somewhat-Bearish | Relevance: 100%
- JPMorgan Chase & Co. has reduced its stake in REGENXBIO Inc. by 11.7%, selling over half a million shares, but still holds 7.63% of the company's stock. Insider selling by CEO Curran Simpson and others totals 36,169 shares in the past three months, while institutional investors own a significant 88.08%. REGENXBIO, despite being unprofitable, has surpassed revenue and EPS estimates, leading analysts to a "Moderate Buy" consensus with a target price of $28.63.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | Chardan Capital | $52 | $52 | 0% |
| 2025-11-07 | RBC Capital | $19 | $17 | +12% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | Chardan Capital | main | Buy |
| 2025-11-07 | RBC Capital | main | Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.26M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 62.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- JPMORGAN CHASE & CO: 16.0% (+109.6%)
- Blackrock Inc.: 12.6% (-5.7%)
- Redmile Group, LLC: 9.3% (-1.7%)
- Vanguard Group Inc: 6.6% (-2.4%)
- State Street Corpora: 3.9% (+7.7%)

### Key Risks

1. Elevated short interest (12.2%): bears positioning against stock.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.26 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.7x). Revenue growth strong at 35% YoY. Analyst sentiment positive (1 raises, avg +12%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $0.7B |
| Beta | 1.14 |
| 52W Range | $5.04 - $15.41 |
| Short Interest | 12.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.26 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from 12.0% to 6.5% (-5.5% in 5 days), indicating relative weakness vs NASDAQ. Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 89th percentile. MRS_5 at 0.9% confirms short-term momentum alignment. AM_20 at 8.8% shows strong absolute momentum above own 20MA. Outperforming sector by 8.0pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +DUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 6.55% (CS: 90) | Strong |
| RSI_14 | 58.4 | Neutral |
| MACD Histogram | 0.10 | Bullish |
| vs SMA20 | 1.088x | Above |
| vs SMA50 | 1.105x | Above |
| vs SMA200 | 1.416x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** STRENGTH

### Trade Setup

- **Entry:** $12.98
- **Stop Loss:** $11.38 (12.3% risk)
- **Target:** $15.38 (R:R method)
- **Risk/Reward:** 1.50:1
- **Target Reasoning:** STRENGTH thesis targets 1.5x risk/reward based on historical edge

### Position Sizing

- **Shares:** 312
- **Position Value:** $4,049.76
- **Portfolio %:** 4.05%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-03-12 (Est: $-0.80)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.30 | $-1.20 | +7.6% |
| 2025Q2 | $-1.05 | $-1.38 | -30.8% |
| 2025Q1 | $0.49 | $0.12 | -75.3% |
| 2024Q4 | $-1.08 | $-1.01 | +6.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*